Fox Run Management L.L.C. Buys New Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Fox Run Management L.L.C. purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 2,161 shares of the company's stock, valued at approximately $339,000.

Other hedge funds also recently added to or reduced their stakes in the company. Entropy Technologies LP acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at about $548,000. Janney Montgomery Scott LLC boosted its holdings in Krystal Biotech by 42.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after acquiring an additional 15,545 shares during the period. Citigroup Inc. grew its position in Krystal Biotech by 65.4% in the third quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after acquiring an additional 13,874 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Krystal Biotech by 9.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company's stock valued at $43,727,000 after purchasing an additional 19,777 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Krystal Biotech by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock worth $19,340,000 after purchasing an additional 3,727 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Chardan Capital raised their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $220.00.

Remove Ads

Krystal Biotech Stock Up 0.6 %

Shares of KRYS traded up $1.17 during mid-day trading on Friday, hitting $183.92. The stock had a trading volume of 224,610 shares, compared to its average volume of 289,479. The company has a market cap of $5.30 billion, a PE ratio of 61.51 and a beta of 0.87. The company's fifty day simple moving average is $170.82 and its two-hundred day simple moving average is $173.55. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm posted $0.30 EPS. The company's revenue for the quarter was up 116.4% on a year-over-year basis. Equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).